tbuckley/cabot-search huggingface dataset:
A Systematic Review of Filtering Facepiece Respirator Reprocessing
Authors: Shlomit Halachmi, Clarence Murray, Aftin Ross
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Benefits of transvenous mitral annuloplasty in heart failure with lower degrees of functional mitral regurgitation. Letter regarding the article ‘Treating symptoms and reversing remodelling: clinical and echocardiographic 1‐year outcomes with percutaneous mitral annuloplasty for mild to moderate secondary mitral regurgitation’
Authors: Michael Dandel, Roland Hetzer
Journal: European Journal of Heart Failure (2021)
Eosinophilia and fractional exhaled nitric oxide levels in chronic obstructive lung disease
Authors: Srinadh Annangi, Snigdha Nutalapati, Jamie Sturgill, Eric Flenaugh, Marilyn Foreman
Journal: Thorax (2021)

COPD is a heterogeneous disorder with varied phenotypes. We aimed to determine the prevalence of asthma history, peripheral eosinophilia and elevated FeNO levels along with the diagnostic utility of peripheral eosinophilia in identifying airway eosinophilic inflammation.National Health and Nutrition Examination Survey data were analysed for the study period 2007-2010. Subjects aged ≥40 years with postbronchodilator FEV1/FVC ratio <0.70 were included. Receiver operator curve analysis was performed for sensitivity analysis. A p value of <0.001 is considered statistically significant.A total of 3 110 617 weighted COPD cases were identified; predominantly male (64.4%) and non-Hispanic whites (86.1%). Among our COPD subjects, 14.6% had a history of doctor diagnosed asthma, highest among females and other race Americans. The overall prevalence of peripheral eosinophilia is 36%, 38.3% among COPD subjects with asthma history, and 35.6% among COPD without asthma history. The overall prevalence of elevated FeNO ≥25 ppb is 14.3%; 28.7% among COPD subjects with asthma history and 13.0% among COPD without asthma history.The prevalence of FeNO levels ≥25 ppb and peripheral eosinophilia was significantly higher among COPD subjects with asthma compared with COPD without asthma history. Not all COPD subjects with peripheral eosinophilia and elevated FeNO levels have a reported history of asthma. Our study supports clinically phenotyping COPD subjects with eosinophilic inflammation be independent of their asthma history and peripheral eosinophilia can be used as a surrogate marker in resource-limited settings.
The germinal center reaction depends on RNA methylation and divergent functions of specific methyl readers
Authors: Amalie C. Grenov, Lihee Moss, Sarit Edelheit, Ross Cordiner, Dominik Schmiedel, Adi Biram, Jacob H. Hanna, Torben Heick Jensen, Schraga Schwartz, Ziv Shulman
Journal: The Journal of Experimental Medicine (2021)

Long-lasting immunity depends on the generation of protective antibodies through the germinal center (GC) reaction. N6-methyladenosine (m6A) modification of mRNAs by METTL3 activity modulates transcript lifetime primarily through the function of m6A readers; however, the physiological role of this molecular machinery in the GC remains unknown. Here, we show that m6A modifications by METTL3 are required for GC maintenance through the differential functions of m6A readers. Mettl3-deficient GC B cells exhibited reduced cell-cycle progression and decreased expression of proliferation- and oxidative phosphorylation–related genes. The m6A binder, IGF2BP3, was required for stabilization of Myc mRNA and expression of its target genes, whereas the m6A reader, YTHDF2, indirectly regulated the expression of the oxidative phosphorylation gene program. Our findings demonstrate how two independent gene networks that support critical GC functions are modulated by m6A through distinct mRNA binders.
Microvesicles transfer mitochondria and increase mitochondrial function in brain endothelial cells
Authors: Anisha D'Souza, Amelia Burch, Kandarp M. Dave, Aravind Sreeram, Michael J. Reynolds, Duncan X. Dobbins, Yashika S. Kamte, Wanzhu Zhao, Courtney Sabatelle, Gina M. Joy, Vishal Soman, Uma R. Chandran, Sruti S. Shiva, Nidia Quillinan, Paco S. Herson, Devika S Manickam
Journal: Journal of Controlled Release (2021)
A Common Electrocardiogram Demonstrating an Uncommon Cause
Authors: Ting-Ting Li, Chuan-Hai Zhang
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Aggregation‐Induced Emission Materials that Aid in Pharmaceutical Research
Authors: Bingnan Wang, Shanshan Liu, Xiaolin Liu, Rong Hu, Anjun Qin, Ben Zhong Tang
Journal: Advanced Healthcare Materials (2021)

Abstract The in situ visualization of drugs can improve the understanding of their pharmacokinetics and mechanisms. Aggregation‐induced emission (AIE) materials, which can aid in the visualization of drugs, are gradually being employed in pharmaceutical research due to their excellent fluorescence properties, good biocompatibility, and extremely high sensitivity. Herein, the progress of AIE materials in pharmaceutical research, including AIE carriers for drug delivery, AIE multifunctional prodrugs, and AIE compounds as bioactive reagents for theranostics is briefly described. Moreover, the opportunities and challenges of AIE materials in pharmaceutical research are discussed in depth. It is believed that versatile AIE materials hold great promise for the promotion of pharmacological research and can facilitate significant advancements in clinical fields.
26331 A systematic review and meta-analysis of cardiovascular events in patients with hidradenitis suppurativa
Authors: Renuka Kannappan, Kelly Pellegrino, William Guo, Hunya Usmani, Jocellie Marquez, Marissa Ayasse, Paige Varney, Joann Salvemini, Richard Clark, Tara Kaufmann
Journal: Journal of the American Academy of Dermatology (2021)
Diagnosis and Immunotherapy of Mould Allergy.
Authors: H.‐J. Malling
Journal: Allergy (1986)

Twenty-four adult asthmatics with autumnal asthma and positive bronchial provocation test to the mould species Cladosporium were evaluated by daily symptoms scores during 11 weeks in the peak mould spore season. A significant association with fluctuation in Cladosporium spore count was found regarding the relative weekly symptom score (mean of subjective asthma and peak flow scores), relative use of antiasthmatic medication and the combined (total) score (mean of symptom and medication scores). The median weekly symptom, medication, and total scores were positively correlated to Cladosporium spore count, but only significantly so in the medication score. Eighteen patients were allergic to both Cladosporium and Alternaria, but asthma symptoms were not associated to Alternaria spore counts; on the contrary, a negative correlation indicated that Alternaria only played a minor role in eliciting asthma. Neither mugwort nor house dust mites seemed to be of importance. The results of diagnostic tests (bronchial provocation test, quantitative skin prick test, RAST and histamine release) were correlated to the mean absolute symptom score of the spore season. The highest correlation to asthma score, peak flow score, medication score, and the combined score was found with the bronchial provocation test. The data indicate that autumnal asthma, to a high degree, is elicited by Cladosporium spores, and further, that the specific allergic diagnosis can only be established by a combination of positive diagnostic tests and careful recording of symptoms elicited by the causative allergen.
P46: Occupational dermatoses during COVID‐19: effect on work and wellbeing
Authors: A Uthayakumar, E Panagou, C Martyn-Simmons
Journal: British Journal of Dermatology (2021)

of this neutrophil activity across EB types may unveil novel therapeutic targets that can be exploited to modulate neutrophil function and the wound microenvironment to accelerate healing in EB.
Mental Health and Substance Use Among Adults with Disabilities During the COVID-19 Pandemic — United States, February–March 2021
Authors: Mark É. Czeisler, Amy Board, JoAnn M. Thierry, Charles A. Czeisler, Shantha M.W. Rajaratnam, Mark E. Howard, Kristie E.N. Clarke
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Adults with disabilities, a group including >25% of U.S. adults (1), experience higher levels of mental health and substance use conditions and lower treatment rates than do adults without disabilities* (2,3).Survey data collected during April-September 2020 revealed elevated adverse mental health symptoms among adults with disabilities (4) compared with the general adult population (5).Despite disproportionate risk for infection with SARS-CoV-2, the virus that causes COVID-19, and COVID-19-associated hospitalization and mortality among some adults with disabilities (6), information about mental health and substance use in this population during the pandemic is limited.To identify factors associated with adverse mental health symptoms and substance use among adults with disabilities, the COVID-19 Outbreak Public Evaluation (COPE) Initiative † administered nonprobability-based Internet surveys to 5,256 U.S. adults during February-March 2021 (response rate = 62.1%).Among 5,119 respondents who completed a two-item disability screener, nearly one-third (1,648; 32.2%) screened as adults with disabilities.These adults more frequently experienced symptoms of anxiety or depression (56.6% versus 28.7%, respectively), new or increased substance use (38.8% versus 17.5%), and suicidal ideation (30.6% versus 8.3%) than did adults without disabilities.Among all adults who had received a diagnosis of mental health or substance use conditions, adults with disabilities more frequently (42.6% versus 35.3%; p <0.001) reported that the pandemic made it harder for them to access related care or medication.Enhanced mental health and substance use screening among adults with disabilities and improved access to medical services are critical during public health emergencies such as the COVID-19 pandemic.During February 16-March 8, 2021, among 8,475 eligible invited respondents aged ≥18 years, 5,261 (62.1%) completed nonprobability based, English-language, Internet-based * https://store.samhsa.gov/sites/default/files/d7/priv/pep19-02-00-002_508_022620.pdf† The COVID-19 Outbreak Public Evaluation (COPE) Initiative (https://www.thecopeinitiative.org/) is designed to assess public attitudes, behaviors, and beliefs related to COVID-19 pandemic and to evaluate mental and behavioral health during the pandemic.The COPE Initiative surveys included in this analysis were administered by Qualtrics, LLC (https://www.qualtrics.com), a commercial survey company with a network of participant pools with varying recruitment methodologies that include digital advertisements and promotions, word-of-mouth and membership referrals, social networks, television and radio advertisements, and offline mail-based approaches.
Prognostic impacts of the change in muscle mass on patients with cirrhosis
Authors: Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Young-Sun Lee, Sun Young Yim, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um
Journal: Journal of Hepatology (2021)
Regeneration of infarcted mouse hearts by cardiovascular tissue formed via the direct reprogramming of mouse fibroblasts
Authors: Jaeyeaon Cho, Sangsung Kim, Hyein Lee, Woongchan Rah, Hee Cheol Cho, Nam Kyun Kim, Seongho Bae, Dong Hoon Shin, Min Goo Lee, In-Hyun Park, Yoshiaki Tanaka, Eric Shin, Hong Yi, Ji Woong Han, Patrick Tae Joon Hwang, Ho-Wook Jun, Hun-Jun Park, Kyuwon Cho, Sang Wook Lee, Jae Kyung Jung, Rebecca D. Levit, Mark A. Sussman, Richard P. Harvey, Young-sup Yoon
Journal: Nature Biomedical Engineering (2021)
27595 Neurokinin-1 receptor antagonist tradipitant improves itch associated with mild atopic dermatitis: Results from EPIONE, a randomized clinical trial
Authors: Jennifer L. Brzezynski, Alyssa R. Kaden, Michael A. Mohrman, Jingyuan Wang, Sandra P. Smieszek, Bartlomiej Przychodzen, Changfu Xiao, Christos Polymeropoulos, Gunther Birznieks, Mihael H. Polymeropoulos
Journal: Journal of the American Academy of Dermatology (2021)
26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE)
Authors: Michael J. Cork, Benjamin Lockshin, Andrew Blauvelt, Zhen Chen, Faisal A. Khokhar, Ashish Bansal, Randy Prescilla
Journal: Journal of the American Academy of Dermatology (2021)
In-hospital and midterm post-discharge complications of adults hospitalised with respiratory syncytial virus infection in France, 2017–2019: an observational study
Authors: Alexandre Descamps, Nezha Lenzi, Florence Galtier, Fabrice Lainé, Zineb Lesieur, Philippe Vanhems, Sélilah Amour, Anne-Sophie L'Honneur, Nadhira Fidouh, Vincent Foulongne, Gisèle Lagathu, Xavier Duval, Corinne Merle, Bruno Lina, Fabrice Carrat, Odile Launay, Paul Loubet
Journal: European Respiratory Journal (2021)

The purpose of this study was to describe the clinical characteristics and in-hospital and post-discharge outcomes of respiratory syncytial virus (RSV) infection among adults hospitalised with influenza-like illness (ILI) and compared against patients admitted for influenza.Adults hospitalised with ILI were prospectively included from five French university hospitals over two consecutive winter seasons (2017/2018 and 2018/2019). RSV and influenza virus were detected by multiplex reverse transcription PCR on nasopharyngeal swabs. RSV-positive patients were compared to RSV-negative and influenza-positive hospitalised patients. Poisson regression models were used to estimate the adjusted prevalence ratio (aPR) associated with in-hospital and post-discharge outcomes between RSV and influenza infections. The in-hospital outcome was a composite of the occurrence of at least one complication, length of stay ≥7 days, intensive care unit admission, use of mechanical ventilation and in-hospital death. Post-discharge outcome included 30- and 90-day all-cause mortality and 90-day readmission rates.Overall, 1428 hospitalised adults with ILI were included. RSV was detected in 8% (114 of 1428) and influenza virus in 31% (437 of 1428). Patients hospitalised with RSV were older than those with influenza (mean age 73.0 versus 68.8 years, p=0.015) with a higher frequency of chronic respiratory or cardiac disease (52% versus 39%, p=0.012, and 52% versus 41%, p=0.039, respectively) and longer hospitalisation duration (median stay 8 versus 6 days, p<0.001). Anti-influenza therapies were less prescribed among RSV patients than influenza patients (20% versus 66%, p<0.001). In-hospital composite outcome was poorer in RSV patients (aPR 1.5, 95% CI 1.1-2.1) than in those hospitalised with influenza. No difference was observed for the post-discharge composite outcome (aPR 1.1, 95% CI 0.8-1.6).RSV infection results in serious respiratory illness, with worse in-hospital outcomes than influenza and with similar midterm post-discharge outcomes.
Reply to: Room for methodological improvement in gait speed study for COPD patients
Authors: Jessica A. Walsh, Ruth E. Barker, Samantha S.C. Kon, Sarah E. Jones, Winston Banya, Claire M. Nolan, Suhani Patel, Oliver Polgar, Brigitte M. Haselden, Michael I. Polkey, Paul Cullinan, William D-C. Man
Journal: European Respiratory Journal (2021)

<b>This study shows 4-m gait speed adds prognostic information for patients following an acute exacerbation of COPD; it should be considered in the development of future risk prediction models with appropriate validation and methodology</b>https://bit.ly/3jTSdED
BRIE2: computational identification of splicing phenotypes from single-cell transcriptomic experiments
Authors: Yuanhua Huang, Guido Sanguinetti
Journal: Genome biology (2021)

Abstract RNA splicing is an important driver of heterogeneity in single cells through the expression of alternative transcripts and as a determinant of transcriptional kinetics. However, the intrinsic coverage limitations of scRNA-seq technologies make it challenging to associate specific splicing events to cell-level phenotypes. BRIE2 is a scalable computational method that resolves these issues by regressing single-cell transcriptomic data against cell-level features. We show that BRIE2 effectively identifies differential disease-associated alternative splicing events and allows a principled selection of genes that capture heterogeneity in transcriptional kinetics and improve RNA velocity analyses, enabling the identification of splicing phenotypes associated with biological changes.
AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
Authors: Antonia Beitzen-Heineke, Nikolaus Berenbrok, Jonas Waizenegger, Sarina Paesler, Victoria Gensch, Florian Udonta, Maria Elena Vargas Delgado, Janik Engelmann, Friederike Hoffmann, Philippe Schafhausen, Gunhild von Amsberg, Kristoffer Riecken, Niklas Beumer, Charles D. Imbusch, James Lorens, Thomas Fischer, Klaus Pantel, Carsten Bokemeyer, Isabel Ben-Batalla, Sonja Loges
Journal: HemaSphere (2021)

BCR-ABL negative myeloproliferative neoplasms (MPNs) consist of essential thrombocythemia, polycythemia vera, and myelofibrosis. The majority of patients harbor the JAK2 -activating mutation V617F. JAK2 inhibitors were shown to reduce symptom burden and splenomegaly in MPN patients. However, treatment options are limited after failure of JAK2 inhibitors. AXL, a member of the TAM family of receptor tyrosine kinases, mediates survival and therapy resistance of different myeloid cancers including acute myeloid leukemia and chronic myeloid leukemia. We studied the relevance of AXL as a target in MPN using primary patient cells and preclinical disease models. We found that AXL is abundantly activated in MPN cells and that its ligand growth arrest-specific gene 6 is upregulated in MPN patients. Pharmacologic and genetic blockade of AXL impaired viability, decreased proliferation and increased apoptosis of MPN cells. Interestingly, ruxolitinib treatment induced increased phosphorylation of AXL indicating that activation of AXL might mediate resistance to ruxolitinib. Consistently, the AXL inhibitor bemcentinib exerted additive effects with ruxolitinib via impaired STAT3, STAT5, and AKT signaling. Both agents had activity when employed alone and exerted an additive effect on survival and splenomegaly in vivo. Moreover, bemcentinib treatment normalized red blood cell count and hemoglobin levels in vivo. Thus, our data indicate that AXL inhibition represents a novel treatment option in MPN warranting clinical investigation.
Hidden data: Public health research is at risk from suppression by governments, study finds
Authors: Gareth Iacobucci
Journal: BMJ (2021)

Researchers around the world have been pressured by government agencies to delay, alter, or not publish the findings of trials that investigate public health interventions, a small study has reported.1

Australian researchers surveyed the lead or corresponding study authors of 208 prevention trials covering nutrition, physical activity, sexual health, smoking, and substance use. The trials were all published from 2007 to 2017 and had been included in a Cochrane review.

Some 104 authors (50%) responded: 35 from North America, 34 from Europe, 18 from Oceania, and 17 from other countries. Of these, a fifth (18/98) reported at least one instance of suppression. The most reported type of suppression (from …